publication venue for
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis 2023
- A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. 57:295-298. 2022
- Longitudinal lung function in childhood cancer survivors after hematopoietic stem cell transplantation. 57:207-214. 2022
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. 57:31-37. 2022
- Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation—a cohort study. 56:1065-1076. 2021
- Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. 55:1093-1102. 2020
- Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. 54:44-52. 2019
- Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. 51:1019-1021. 2016
- NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. 49:1513-1520. 2014
- Malnutrition in patients with chronic GVHD. 49:1300-1306. 2014
- Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. 49:116-121. 2014
- Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. 46:516-522. 2011
- Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group. 45:1253-1255. 2010
- Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. 45:521-526. 2010
- Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. 44:413-425. 2009
- A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. 44:317-320. 2009
- Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. 42:51-56. 2008
- Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. 41:743-747. 2008
- Undetectable leukemic blasts and absence of NOD/SCID leukemia-initiating cells in cord blood from a case of maternal AML. 36:269-270. 2005
- Hematopoietic capacity of adult human skeletal muscle is negligible. 35:663-666. 2005
- Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. 35:51-55. 2005
- Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age. 32:1135-1143. 2003
- Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets. 30:851-860. 2002
- Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. 29:967-972. 2002
- Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. 29:967-972. 2002
- Decreased bone mineral density is common after autologous blood or marrow transplantation. 28:387-391. 2001
- Donor leukocyte infusions for multiple myeloma. 26:1179-1184. 2000
- Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy. 26:859-864. 2000
- Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. 24:641-645. 1999
- Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. 24:637-640. 1999
- Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. 23:203-209. 1999
- Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. 23:397-399. 1999
- Parentage testing implications of male fertility after allogeneic bone marrow transplantation. 23:187-189. 1999
- The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. 23:45-51. 1999
- Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. 22:1199-1205. 1998
- CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. 22:947-955. 1998
- Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. 21:769-773. 1998
- Neutropenic fever in patients after high-dose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor. 14:989-90. 1994
- Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.. 12:405-407. 1993
- Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.. 8:477-487. 1991
- Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.. 7:183-191. 1991
- International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation 2022
- Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide based T cell-replete Haploidentical Hematopoietic Stem Cell Transplantation 2020
- Late hospitalizations among survivors of childhood, adolescence and young adulthood hematopoietic stem-cell transplantation performed for malignant indications 2019
- Low dose cytarabine may prevent hematologic relapse prior to hsct in patients with AML in first complete remission with minimal residual disease 2019
- subsequent malignant neoplasms after pediatric, adolescent and young adulthood stem-cell transplantation: a population-based cohort 2019
- Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD 2018
- Intensified conditioning with fludarabine/melphalan plus total body irradiation for acute myeloid leukemia with minimal residual or active disease 2018
- Ongoing recurrent hospitalization, malignancy, and mortality among survivors of childhood hematopoietic stem cell transplantation performed for non-malignant indications 2018
- Inotuzumab ozogamicin and DLI can induce molecular remission in acute lymphoblastic leukemia relapse after allogeneic HSCT 2017
- Outcome of allogeneic stem cell transplantation for patients with high-risk acute leukemia according to donor type and graft-versus-host disease prophylaxis 2017
- Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL 2016
- Five-Year Outcomes of Halt-MS: High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing-Remitting Multiple Sclerosis 2016
- CD34 CELL DOSE IS CORRELATED WITH HEMATOLOGIC RECOVERY BUT NOT CHRONIC GVHD: RESULTS OF THE CBMTG TRIAL COMPARING G-CSF-MOBILIZED PERIPHERAL BLOOD(G-PB) VS G-CSF STIMULATED BONE MARROW(G-BM) IN SIBLING ALLOGRAFTS FOR HEMATOLOGIC MALIGNANCIES 2014
- DONOR B CELLS POPULATIONS, IFNG-PRODUCING T CELLS, AND CD56BRIGHT NK CELLS CORRELATE WITH DEVELOPMENT OF CHRONIC GVHD IN G-CSF STIMULATED SIBLING DONOR PERIPHERAL BLOOD AND BONE MARROW: RESULTS FROM THE CANADIAN BMT GROUP 0601 RANDOMIZED, PHASE III TRIAL 2014
- SELECTIVE PHOTODEPLETION OF RECIPIENT-ALLOREACTIVE T-CELLS ENABLES SAFE AND EFFICACIOUS HAPLOIDENTICAL HSCT: INTERIM RESULTS FROM A PHASE II TRIAL IN PATIENTS WITH AML, ALL, AND MDS 2014
- Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable 2013
- Allogeneic-related stem cell transplantation with reduced-intensity conditioning versus best standard of care in older patients with acute myeloid leukaemia in first complete remission. Interim analysis of a prospective multi center phase III trial 2010
- Granulocyte-colony stimulating factor - impact on haemostasis in allogeneic stem cell donors. A prospective study 2008
- Outcomes of reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma - national review of the Canadian experience by the Canadian Blood and Marrow Transplant Group 2008